Press Releases Burning Rock Biotech Limited

Equities

BNR

US12233L2060

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-03 pm EDT			5-day change	1st Jan Change
7.49 ^USD	+4.76%		-0.79%	-19.46%

May. 30	Burning Rock Biotech to Work With Bayer to Increase Patient Access to Precision Cancer Medicines in China	MT
May. 30	Bayer and Burning Rock Biotech Limited Collaborates to Increase Patient Access to Precision Cancer Medicines	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement	Jun. 03	AQ
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines	May. 30	AQ
Burning Rock Biotech : First Quarter 2024 Financial Results	May. 29	PU
Burning Rock Reports First Quarter 2024 Financial Results	May. 29	AQ
Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024	May. 23	AQ
Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024	May. 14	GL
BURG ROCK : Burning Rock ADS Ratio Change	May. 09	PU
Burning Rock Publishes 2023 Annual Report on Form 20-F	Apr. 29	GL
Burning Rock Biotech : 2023 Annual Report	Apr. 29	PU
Burning Rock Announces ADS Ratio Change	Apr. 26	GL
Burning Rock Announces ADS Ratio Change	Apr. 26	AQ
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 28	GL
Burning Rock Announces Receipt of Notification from NASDAQ	Jan. 04	GL
Burning Rock Announces Results of 2023 Annual General Meeting	Dec. 19	GL
Burning Rock Reports Third Quarter 2023 Financial Results	Nov. 30	GL
Burning Rock Announces 2023 Annual General Meeting to be Held on December 20, 2023	Nov. 22	GL
Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023	Nov. 20	GL
Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics	23-10-30	GL
Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test	23-10-15	GL
Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell	23-09-07	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Burning Rock Biotech Limited

Equities

BNR

US12233L2060

Press Releases

Filters